48 Top Stock Pitches (26th-1st November) [NO PAYWALL] 🖨️
Capital Employed rounds up 48 stock pitches, led by Greystone’s $14.50 target for organ-transplant logistics firm Strata Critical Medical, versus $4.70.
Capital Employed rounds up 48 stock pitches, led by Greystone’s $14.50 target for organ-transplant logistics firm Strata Critical Medical, versus $4.70.
Our Q2 letter is up on Voss Cap website now. We give a brief overview of our $IIIV investment thesis. https://t.co/NgmaY6IhKN
Here is what @AlderLaneEggs had to say on the FinTwit battleground stock $ENVX in Idea Brunch today https://t.co/bcETHlsKYT
.@ClarkSquareCap on $GRVY Read more in their Idea Brunch interview out today! https://t.co/v7Y3r1OmBm
We interviewed Michael Melby, one of the most talented microcap investors of our generation Michael shares his approach to interviewing management teams, his research process, and some top ideas $UNTC $ALCO Read on! https://t.co/TGUA9dCa4Y
New Idea Brunch interview with @longcastadviser just dropped Tickers mentioned: $MTRX & $MMMB https://t.co/TeYUbiEzWi
Check out our latest interview with Brian Finn of @fin_capital Brian discusses his recent activist letter at $OPRT and shares some other ideas! https://t.co/sgPhNzCg77
Had a blast publishing this interview with @aaronjsallen. Aaron is a phenomenal small/mid-cap investor and shares his research process and some ideas in this Idea Brunch interview Tickers mentioned: $UBAB, $RCKY, $WHG, and $RFIL https://t.co/fgvQX74K8m
Just published an Idea Brunch with Jad Fakhry of Poplar Point Capital! Jad knows a ton about the microcap landscape and shares some interesting ideas $MCEM $AMNF $CTG $SPCO https://t.co/gADss5LzBk
Travelzoo’s roughly 400,000 prepaid members generate deferred revenue while acquisition costs hit GAAP earnings immediately, masking the…
Aura Biosciences expects pivotal Phase 3 bel-sar data in early choroidal melanoma in 2027, funded by $323.8 million of cash into the first…
Markel spent $315 million repurchasing shares in Q3 as Thrive agreed to buy ADT for $7.6 billion and Hasbro cited rising adult toy demand.
One Stop Systems grew Q3 continuing-operations revenue 36% to $12.6 million, raised FY2026 revenue guidance to $45 million, and used $11.8…
Build-A-Bear’s lease overhaul, off-mall expansion and partner-led wholesale growth reshaped a debt-free retailer with $80 million EBITDA,…
Mattel, Winnebago and PayPal lead 37 special situations spanning activist campaigns, buybacks, M&A and strategic alternatives.
Duos Technologies, DUOT, has shifted to modular edge data center pods, with Q2 revenue up 30% to $6.18 million and FY27 revenue guided…
Daktronics, the leader in U.S. sports video boards, targets 10-12% EBIT margins after shifting production to China and Mexico and exiting…
Build-A-Bear Workshop’s failed pre-made toy line compressed margins, but resilient children’s sales support a $39.39 fair value estimate…
A four-layer 10-K framework tests revenue timing, receivables, reserves and depreciation against cash flow, using Hertz’s 2012-14…
ONT · long Onterris, formerly Montrose Environmental Group, trades at 8.6x next-12-month EBITDA as an environmental consulting and response services…
CarParts.com insiders bought $2 million of PRTS ahead of its December third-party marketplace launch, as cost cuts and new membership,…
Getty Images' 2026 Chapter 11 filing is challenged as a prepack after warrant litigation, a failed Shutterstock merger and AI pressure.
Kingstone Company is replacing quota-share cessions with catastrophe reinsurance, lifting quarterly EBIT margin to 29% from a 24% sector…
Six Value Line small caps including Blackbaud, Marqeta, Ranger Energy and Definitive Healthcare trade on net cash, buybacks, low multiples…
ERock’s modular microgrids bridge data-center power gaps years before grid interconnects, with Meta and Anthropic projects filling capacity…
Unicycive’s oxylanthanum carbonate NDA earned a March 25, 2027 PDUFA date after two manufacturing-related rejections, with no FDA clinical…
Bumble agreed to a $6.05-per-share cash sale to Ithaca Holdings, 136% above its October 2 share price.
Gloo faces related-party deals, insider-heavy IPO ownership, acquisition losses and $84.5 million of CEO-backed puts as it burns cash and…
Sagimet Biosciences' denifanstat enters a fully funded U.S. acne registration trial after Phase 3 results, with SGMT trading below cash and…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.